Does the media prefer RXRX or CRSP?

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.60 beat Recursion Pharmaceuticals' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or ABVX?

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 3 mentions for Abivax. Abivax's average media sentiment score of 0.59 beat Recursion Pharmaceuticals' score of 0.23 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYTK or RXRX?

In the previous week, Cytokinetics had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 9 mentions for Cytokinetics and 8 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.23 beat Cytokinetics' score of 0.19 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RXRX or SYRE?

In the previous week, Spyre Therapeutics had 21 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 29 mentions for Spyre Therapeutics and 8 mentions for Recursion Pharmaceuticals. Spyre Therapeutics' average media sentiment score of 0.31 beat Recursion Pharmaceuticals' score of 0.23 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 6 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Recursion Pharmaceuticals (RXRX) Competitors

$4.63 -0.15 (-3.05%)

As of 11:51 AM Eastern

Compare

RXRX vs. CRSP, ABVX, CYTK, PRAX, and SYRE

Should you buy Recursion Pharmaceuticals stock or one of its competitors? Recursion Pharmaceuticals's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Abivax (ABVX), Cytokinetics (CYTK), Praxis Precision Medicines (PRAX), and Spyre Therapeutics (SYRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Recursion Pharmaceuticals has a net margin of -945.94% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Recursion Pharmaceuticals currently has a consensus target price of $8.06, indicating a potential upside of 68.62%. CRISPR Therapeutics has a consensus target price of $67.94, indicating a potential upside of 18.49%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.67

In the previous week, Recursion Pharmaceuticals and Recursion Pharmaceuticals both had 8 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.60 beat Recursion Pharmaceuticals' score of 0.23 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CRISPR Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	34.27	-$644.76M	-$1.04	N/A
CRISPR Therapeutics	$11M	504.03	-$581.60M	-$4.76	N/A

Summary

CRISPR Therapeutics beats Recursion Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Abivax?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 3 mentions for Abivax. Abivax's average media sentiment score of 0.59 beat Recursion Pharmaceuticals' score of 0.23 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Abivax	N/A	-91.69%	-71.96%

Abivax has lower revenue, but higher earnings than Recursion Pharmaceuticals. Abivax is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	34.27	-$644.76M	-$1.04	N/A
Abivax	N/A	N/A	-$380.27M	-$6.06	N/A

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Abivax has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Recursion Pharmaceuticals presently has a consensus target price of $8.06, indicating a potential upside of 68.62%. Abivax has a consensus target price of $156.69, indicating a potential upside of 70.82%. Given Abivax's stronger consensus rating and higher possible upside, analysts plainly believe Abivax is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Recursion Pharmaceuticals and Abivax tied by winning 8 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytokinetics has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Cytokinetics presently has a consensus price target of $106.00, suggesting a potential upside of 69.06%. Recursion Pharmaceuticals has a consensus price target of $8.06, suggesting a potential upside of 68.62%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.85
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Cytokinetics had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 9 mentions for Cytokinetics and 8 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.23 beat Cytokinetics' score of 0.19 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Recursion Pharmaceuticals has a net margin of -945.94% compared to Cytokinetics' net margin of -1,321.12%. Cytokinetics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Recursion Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	88.62	-$784.96M	-$7.22	N/A
Recursion Pharmaceuticals	$74.68M	34.27	-$644.76M	-$1.04	N/A

Summary

Recursion Pharmaceuticals beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

Praxis Precision Medicines has a beta of 2.79, suggesting that its stock price is 179% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Praxis Precision Medicines' return on equity of -34.15% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%

Praxis Precision Medicines has higher earnings, but lower revenue than Recursion Pharmaceuticals. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	925.96	-$303.27M	-$12.93	N/A
Recursion Pharmaceuticals	$74.68M	34.27	-$644.76M	-$1.04	N/A

Praxis Precision Medicines currently has a consensus target price of $612.42, indicating a potential upside of 115.98%. Recursion Pharmaceuticals has a consensus target price of $8.06, indicating a potential upside of 68.62%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.95
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 8 mentions for Recursion Pharmaceuticals and 3 mentions for Praxis Precision Medicines. Recursion Pharmaceuticals' average media sentiment score of 0.23 beat Praxis Precision Medicines' score of 0.00 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Praxis Precision Medicines beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Spyre Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	34.27	-$644.76M	-$1.04	N/A
Spyre Therapeutics	$890K	9,161.57	-$155.20M	-$1.95	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Spyre Therapeutics had 21 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 29 mentions for Spyre Therapeutics and 8 mentions for Recursion Pharmaceuticals. Spyre Therapeutics' average media sentiment score of 0.31 beat Recursion Pharmaceuticals' score of 0.23 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	6 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Spyre Therapeutics' return on equity of -30.74% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Recursion Pharmaceuticals presently has a consensus target price of $8.06, indicating a potential upside of 68.62%. Spyre Therapeutics has a consensus target price of $109.71, indicating a potential upside of 18.33%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the broader market.

Summary

Spyre Therapeutics beats Recursion Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.37B	$3.87B	$7.21B	$13.45B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-4.26	12.97	274.11	26.40
Price / Sales	31.94	1,229.81	598.93	87.11
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	2.08	16.58	11.07	6.43
Net Income	-$644.76M	-$23.20M	$3.49B	$381.07M
7 Day Performance	10.57%	-2.60%	-1.23%	0.04%
1 Month Performance	22.75%	-10.60%	-5.90%	-4.20%
1 Year Performance	-19.42%	16.52%	7.19%	2.03%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	2.0059 of 5 stars	$4.63 -3.1%	$8.06 +73.9%	-12.9%	$2.48B	$74.68M	N/A	600	News Coverage Options Volume High Trading Volume
CRSP CRISPR Therapeutics	2.3346 of 5 stars	$54.23 -2.6%	$67.94 +25.3%	-15.4%	$5.39B	$3.51M	N/A	393	Gap Up
ABVX Abivax	2.6026 of 5 stars	$91.06 -4.0%	$156.69 +72.1%	+9.3%	$8.29B	N/A	N/A	69	Gap Up
CYTK Cytokinetics	2.2193 of 5 stars	$64.66 -1.5%	$103.37 +59.9%	+10.1%	$8.17B	$88.04M	N/A	673	Analyst Downgrade
PRAX Praxis Precision Medicines	2.4153 of 5 stars	$280.78 -0.4%	$612.42 +118.1%	+421.4%	$7.87B	$8.55M	N/A	110	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CRSP, ABVX, CYTK, PRAX, and SYRE

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Abivax?

Summary

How does Recursion Pharmaceuticals compare to Cytokinetics?

Summary

How does Recursion Pharmaceuticals compare to Praxis Precision Medicines?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. CRSP, ABVX, CYTK, PRAX, and SYRE

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

Do institutionals & insiders have more ownership in RXRX or CRSP?

Which has more volatility and risk, RXRX or CRSP?

Is RXRX or CRSP more profitable?

Do analysts prefer RXRX or CRSP?

Does the media prefer RXRX or CRSP?

Which has preferable valuation & earnings, RXRX or CRSP?

Summary

How does Recursion Pharmaceuticals compare to Abivax?

Does the media refer more to RXRX or ABVX?

Is RXRX or ABVX more profitable?

Which has higher earnings & valuation, RXRX or ABVX?

Which has more volatility & risk, RXRX or ABVX?

Do analysts prefer RXRX or ABVX?

Do institutionals and insiders believe in RXRX or ABVX?

Summary

How does Recursion Pharmaceuticals compare to Cytokinetics?

Do insiders & institutionals hold more shares of CYTK or RXRX?

Which has more volatility and risk, CYTK or RXRX?

Do analysts rate CYTK or RXRX?

Does the media prefer CYTK or RXRX?

Is CYTK or RXRX more profitable?

Which has preferable earnings & valuation, CYTK or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Praxis Precision Medicines?

Which has more risk and volatility, PRAX or RXRX?

Is PRAX or RXRX more profitable?

Which has preferable valuation and earnings, PRAX or RXRX?

Do analysts rate PRAX or RXRX?

Do insiders and institutionals have more ownership in PRAX or RXRX?

Does the media prefer PRAX or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Spyre Therapeutics?

Which has higher valuation and earnings, RXRX or SYRE?

Do institutionals and insiders have more ownership in RXRX or SYRE?

Does the media refer more to RXRX or SYRE?

Is RXRX or SYRE more profitable?

Do analysts rate RXRX or SYRE?

Which has more risk & volatility, RXRX or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools